Consenso uruguayo de manejo del infarto agudo de ... - SciELO

Reperfusion Alternatives Evaluation (BRAVE) Study Investigators.
Early administration of reteplase plus abciximab vs abciximab alone in
patients with acute myocardial infarction referred for percutaneous coronary
intervention: a randomized controlled trial. JAMA 2004; 291: 947-54.
93. ISIS-2 (Second International Study of Infarct Survival)
Collaborative Group. Randomised trial of intravenous streptokinase, oral
aspirin, both, or neither among 17,187 cases suspected acute myocardial
infarction: ISIS-2. Lancet 1988; 2: 349-60.
94. Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary
reocclusion and recurrent ischemia after thrombolysis: a metaanalysis. J Am
Coll Cardiol 1992; 19: 671-7.
95. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-
86.
96. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent
in cardiovascular disease: a statement for healthcare professionals from the
American Heart Association. Circulation 1997; 96: 2751-3.
97. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico. GISSI-2: a factorial randomised trial of alteplase versus
streptokinase and heparin versus no heparin among12,490 patients with
acute myocardial infarction. Lancet 1990; 336: 65-71.
98. The International Study Group. In-hospital mortality and clinical
course of 20,891 patients with suspected acute myocardial infarction
randomised between alteplase and streptokinase with or without heparin.
Lancet 1990; 336: 71-5.
99. ISIS-3 (Third International Study of Infarct Survival)
Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs
tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs
aspirin alone among41,299 cases of suspected acute myocardial infarction.
Lancet 1992; 339: 753-70.
100. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and
fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med
1997; 336: 847-60.
101. The GUSTO Angiographic Investigators. The effects of tissue
plasminogen activator, streptokinase, or both on coronary-artery patency,
ventricular function, and survival after acute myocardial infarction. N Engl J
Med 1993; 329: 1615-22.
102. Assessment of the Safety and Efficacy of a NewThrombolytic
Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin: the
ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;
358: 605-13.
103. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey
AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination